Payment overview · 2025
General Payments
$177.33
9 reported records · 8 companies
Healthcare provider profile · identity verified
Amanda Baxa, MD
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA, KS · NPI 1366703100
Verified facts
What the public records show
CMS Open Payments records show Amanda Baxa, MD received $177.33 in general payments during 2025 across 9 reported records.
PFIZER INC. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.68 | 21.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.44 | 14.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.25 | 13.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.77 | 11.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.59 | 10.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.08 | 10.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.02 | 9.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.50 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $177.33 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 24 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
191 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 624 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 554 | 94 |
| Potassium Chloride | Potassium Chloride | 439 | 71 |
| Losartan Potassium | Losartan Potassium | 426 | 78 |
| Lisinopril | Lisinopril | 384 | 67 |
| Simvastatin | Simvastatin | 346 | 60 |
| Omeprazole | Omeprazole | 344 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 55 |
| Sertraline Hcl | Sertraline Hcl | 294 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 266 | 64 |
| Furosemide | Furosemide | 263 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 240 | 34 |
| Metformin Hcl | Metformin Hcl | 240 | 47 |
| Gabapentin | Gabapentin | 233 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 41 |
| Eliquis | Apixaban | 191 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 27 |
| Warfarin Sodium | Warfarin Sodium | 153 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 23 |
| Jardiance | Empagliflozin | 127 | 16 |
| Allopurinol | Allopurinol | 124 | 20 |
| Metformin Hcl Er | Metformin Hcl | 122 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 16 |
| Montelukast Sodium | Montelukast Sodium | 100 | 13 |
| Alendronate Sodium | Alendronate Sodium | 99 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 19 |
| Famotidine | Famotidine | 96 | 15 |
| Synthroid | Levothyroxine Sodium | 94 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | suppressed |
| Atenolol | Atenolol | 86 | 17 |
| Spironolactone | Spironolactone | 86 | 12 |
| Carvedilol | Carvedilol | 85 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 14 |
| Donepezil Hcl | Donepezil Hcl | 84 | 11 |
| Lorazepam | Lorazepam | 82 | 14 |
| Ozempic | Semaglutide | 82 | 13 |
| Buspirone Hcl | Buspirone Hcl | 80 | 16 |
| Glipizide Er | Glipizide | 80 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 11 |
| Trazodone Hcl | Trazodone Hcl | 72 | suppressed |
| Lovastatin | Lovastatin | 71 | 14 |
| Xarelto | Rivaroxaban | 71 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | suppressed |
| Glipizide | Glipizide | 64 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Prednisone | Prednisone | 61 | 31 |
| Farxiga | Dapagliflozin Propanediol | 59 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 14 |
| Cephalexin | Cephalexin | 56 | 37 |
| Finasteride | Finasteride | 54 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Bumetanide | Bumetanide | 51 | suppressed |
| Tradjenta | Linagliptin | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 21 |
| Estradiol | Estradiol | 46 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 11 |
| Meloxicam | Meloxicam | 41 | 14 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Celecoxib | Celecoxib | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Fentanyl | Fentanyl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 24 |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 25 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 16 |
| Torsemide | Torsemide | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Sulfasalazine | Sulfasalazine | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Verapamil Sr | Verapamil Hcl | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Nystatin | Nystatin | 19 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Nyamyc | Nystatin | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $177.33 · 9 records | PFIZER INC. | ABRYSVO, BREZTRI, COMIRNATY, CONTRAVE, Dexcom G6 Transmitter, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, SYMPLICITY G3, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error